药时代上海报道
随着新冠病毒感染肺炎疫情的日趋严重,呼吁FDA加快新疗法和疫苗研发速度的呼声与日俱增,FDA承受的政治压力不断加大。在这个特殊的时刻,FDA制定了一项紧急计划,以加快新型冠状病毒治疗方法的开发。FDA认为,通过重新调兵遣将,它可以在收到COVID-19相关的要求后的24小时内作出回应,对方案进行审评。
Coronavirus Treatment Acceleration Program
(CTAP)
FDA has created a special emergency program for possible therapies, the Coronavirus Treatment Acceleration Program (CTAP). It uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful. We continue to support clinical trials that are testing new treatments for COVID so that we gain valuable knowledge about their safety and effectiveness.
Snapshot for Developing Therapeutics
Given the urgent nature of the pandemic and the number of companies and researchers developing COVID-19 related therapies, the following numbers may change frequently. Our current snapshot is:
-
10 therapeutic agents in active trials
-
Another 15 therapeutic agents in planning stages
Please send requests for product development for proposed COVID-19 uses and drug development to: COVID19-productdevelopment@fda.hhs.gov. Thank you
Examples of CTAP in Action
-
Immediately upon receipt, triaged requests from developers and scientists seeking to develop or evaluate new drug and biologic therapies, getting the right FDA staff in touch with them and the work to get studies going fast. With a first wave of requests behind us, FDA will generally respond within a day.
-
Provided ultra-rapid, interactive input on most development plans. Interactions are generally prioritized based on a product’s scientific merits, stage of development, and identification as a possible priority product in consensus USG documents. -
Provided ultra-rapid protocol review – within 24 hours of submission, in many cases.
-
Completed review of single patient expanded access requests around-the-clock – and generally within 3 hours.
-
Worked closely with applicants and other regulatory agencies to expedite quality assessments for products to treat COVID-19 patients and to transfer manufacturing to alternative or new sites to avoid supply disruption.
Support for CTAP
-
Redeployed medical and regulatory staff to review teams dedicated to COVID-19 therapies. -
Involved senior management in review of submissions. -
Redeployed medical, operations, and policy staff to support the overall effort. -
Streamlined processes and operations for developers and scientists to send us inquiries and requests. -
Provided resources to healthcare providers and researchers to help them submit emergency requests to use investigational products for patients with COVID-19 infections.
We will continue to enhance and expand CTAP. To the extent permitted by confidentiality laws, we’ll post summary statistics, keep the public updated, and link to public information about ongoing clinical trials and to summaries of drugs in clinical and preclinical development.
参考资料:
-
FDA官网:Coronavirus Treatment Acceleration Program (CTAP)
-
FDA官网:Coronavirus (COVID-19) Update: FDA Continues to Accelerate Development of Novel Therapies for COVID-19
-
FDA creates program to speed up coronavirustherapies(By Nick Paul Taylor Apr 1, 20208:21am)
-
内容仅供感兴趣的个人谨慎参考,非商用,非医用、非投资用。版权归作者。衷心感谢! -
时间、水平有限,错误偏颇难免。欢迎朋友们指正!了解详情,请阅读原文。 -
任何问题,请与我们联系!谢谢!

Peter Baker先生数据可靠性培训直播系列 | 课程介绍



-
更多活动策划筹备中

发布者:药时代,转载请首先联系contact@drugtimes.cn获得授权